Fractyl Health

Did you know that #obesity disproportionately impacts women? Nearly 42% of adult women in the U.S. live with obesity, placing them at increased risk for conditions like #heartdisease, #diabetes, and certain #cancers. Raising awareness and advancing solutions are essential steps towards improving women’s health outcomes. Women are the foundation of families and communities, often juggling multiple roles as professionals, caregivers and leaders. Their health and well-being are crucial – not just for themselves, but for society overall. When women thrive, communities flourish. Research, advocacy, and access to effective treatments all play a role in addressing this public health crisis. At Fractyl, we’re breaking the pattern of obesity treatment by addressing the root cause of this disease, to help ensure that women have the support they need to take charge of their health. #FractylForward #IWD2025 #WomensHistoryMonth #ObesityAwareness #WomenInHealth

We’re breaking the pattern of #obesity and?#T2D. Read more about Fractyl Health’s (#NASDAQ: $GUTS) Q4 and Full Year 2024 financial results and our potentially novel approach to weight maintenance here: https://bit.ly/3F4RQnl Tune in now:?https://bit.ly/3D1KikB #FractylHealthNews #FractylForward

UPCOMING: We’re pleased to share our Q4 and full year 2024 #earnings on Monday, March 3, at 4:30 PM ET. ? Join us for the live webcast: https://bit.ly/3D1KikB ? #NASDAQ: $GUTS #FractylForward

Our Co-Founder & CEO, Harith Rajagopalan, is featured in the latest PharmaVoice Biotech Spotlight, diving into our #obesity pipeline and #T2D gene therapy.?We anticipate multiple readouts in 2025 that have the potential to shape the future of metabolic disease treatment. Explore the feature to see what’s ahead:?https://lnkd.in/g2ATgZyU #FractylForward

Participation in the REMAIN-1 pivotal study remains strong. Learn more about how we are targeting a root cause of obesity, and meeting the unmet need of weight maintenance, here: https://lnkd.in/e3kDQw52. *Revita is for investigational use only in the US under Federal law. #FractylForward #obesity?

Today, we announced we are prioritizing our REMAIN-1 study, addressing an unmet need for an off-ramp to GLP-1 drugs, while advancing our novel Rejuva gene therapy platform into first-in-human studies. Read more about the announcement: https://bit.ly/4hBa1ir $GUTS #FractylForward #ObesityData #Obesity

The Fractyl team had a fantastic week at #JPM25. We’re excited to build on this momentum as we advance our pipeline of novel therapies that target root causes of obesity and type 2 diabetes. Learn more about our approach here: https://lnkd.in/e67c-avY. ? #FractylForward #JPM25 #obesity

BREAKING: We're excited to announce promising initial clinical results from the first patient in the REVEAL-1 open-label?cohort of our REMAIN-1 study. We're seeing positive results after one month of #GLP1 drug discontinuation alongside the Revita procedure, in line with trends observed in prior Revita clinical studies. Additionally, we're reporting significant progress in our REMAIN-1 pivotal study, evaluating weight maintenance after GLP-1 discontinuation. With more than 100 patients enrolled across the first 8 clinical study sites in less than 4 months since first site activation, this milestone reflects strong engagement from both #patients and #physicians. Read?more about today's announcements: https://bit.ly/40u8Hbl $GUTS #FractylForward #ObesityData?#Obesity

We look forward to connecting with industry peers and learning about the latest insights in #healthcare at J.P. Morgan’s 43rd Annual Healthcare Conference in San Francisco! We hope to see you there. $GUTS #FractylForward #JPM2025

We’ve had a banner year at Fractyl Health. From going public, to presenting compelling data across the country to investors and scientists and receiving a Breakthrough Device?designation from the FDA - we're celebrating our successes and looking #FractylForward to a big 2025 full of critical catalysts. We're deeply appreciative of our employees, our Board, our investors, our physician partners, and most importantly our patients for propelling us forward each day and making significant strides in the fight against #obesity and #T2D. We look forward to continuing this momentum in 2025!